EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy in the Treatment of Soft Tissue Sarcoma Since SARC028: An NCDB Analysis

Galileo S Dumont iD, Hanna L Gratny, Carson Keeter iD, Breelyn A Wilky iD, Ryan Lanning iD, Nathan J Donaldson, Steven W Thorpe iD

Journal of Surgical Oncology · 2026-11 · 134 (6) · 927-938

DOI: 10.1002/jso.70371 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Surgical Oncology, online erschienen am 12.08.2026. Verfasst von Galileo S Dumont und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Sarcoma, Immunotherapy, Soft Tissue Neoplasms. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The publication of SARC028 in late 2017 revolutionized soft tissue sarcoma (STS) treatment by demonstrating promising response to anti‐PD1 immunotherapy in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS). Data on immunotherapy efficacy and outcomes in larger cohorts and with longer follow‐up remain limited.

Methods

31 672 cases of UPS, DDLPS, alveolar soft part sarcoma, and myxofibrosarcoma were extracted from the NCDB. Factors associated with the use of immunotherapy were evaluated using logistic regression, and survival analysis was performed with Kaplan‐Meier curves and Cox proportional hazards models.

Results

Patients diagnosed with STS after 2017 were 3.67 times more likely to receive immunotherapy. Immunotherapy was associated with an approximately 20% reduction in mortality in stage IV STS, which was driven by cases of UPS. This survival benefit was observed in male, but not female, patients. There was no survival benefit in stage III STS.

Discussion

These data are consistent with a survival benefit with immunotherapy in stage IV STS, predominantly in UPS, supporting the findings of SARC028. Benefit in stage III STS was not observed, limiting concordance with later trials like SARC032. Further prospective data on long‐term outcomes and immunotherapy efficacy according to histology and sex are needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcomaImmunotherapySoft Tissue NeoplasmsHumansFemaleMaleSurvival RateMiddle AgedAged

Stichwörter der Autor:innen

PD1 inhibitorSARC028immunotherapypembrolizumabsoft tissue sarcoma

Autor:innen und Institutionen

  • University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Orthopedic Surgery, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • University of Colorado Cancer Center, Aurora, Colorado, USA.
  • Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado, USA.

ORCID-Profile: Galileo S Dumont, Carson Keeter, Breelyn A Wilky, Ryan Lanning, Steven W Thorpe

Zitieren

APA

Dumont, G. S., Gratny, H. L., Keeter, C., Wilky, B. A., Lanning, R., Donaldson, N. J., & Thorpe, S. W. (2026). Immunotherapy in the Treatment of Soft Tissue Sarcoma Since SARC028: An NCDB Analysis. Journal of Surgical Oncology, 134(6), 927-938. https://doi.org/10.1002/jso.70371

Vancouver

Dumont GS, Gratny HL, Keeter C, Wilky BA, Lanning R, Donaldson NJ, et al. Immunotherapy in the Treatment of Soft Tissue Sarcoma Since SARC028: An NCDB Analysis. Journal of Surgical Oncology. 2026;134(6):927-938. doi:10.1002/jso.70371

BibTeX
@article{Dumont2026,
  author = {Dumont, Galileo S and Gratny, Hanna L and Keeter, Carson and Wilky, Breelyn A and Lanning, Ryan and Donaldson, Nathan J and Thorpe, Steven W},
  title = {Immunotherapy in the Treatment of Soft Tissue Sarcoma Since SARC028: An NCDB Analysis},
  journal = {Journal of Surgical Oncology},
  year = {2026},
  volume = {134},
  number = {6},
  pages = {927--938},
  doi = {10.1002/jso.70371}
}
Kostenlos starten →